Ignite Creation Date:
2024-05-06 @ 3:53 AM
Last Modification Date:
2024-10-26 @ 11:40 AM
Study NCT ID:
NCT02401828
Status:
COMPLETED
Last Update Posted:
2020-01-28
First Post:
2015-03-19
Brief Title:
The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial
Sponsor:
Erasmus Medical Center
Organization:
Erasmus Medical Center
Study Overview
Official Title:
The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial
Status:
COMPLETED
Status Verified Date:
2020-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DOMONO
Brief Summary:
48-week open label randomized phase IV investigator initiated intervention study The purpose of this study is to evaluate whether HIV-1 suppression can be maintained by DTG monotherapy in HIV-1 infected virologically suppressed patients on cART
104 adults fulfilling the in and exclusion criteria and on stable cART will be randomized over 2 investigational arms
The first arm will contain the direct switch population This population will switch directly from stable cART to Dolutegravir mono-therapy on baseline visit
The second arm will contain the delayed-switch population This group will switch from stable cART to Dolutegravir monotherapy 24 weeks after baseline visit
The main goal is to investigate if Dolutegravir mono-therapy could be non-inferior to cART in virological suppressed HIV-1 infected adults
If a interim analysis performed when 40 patients on dolutegravir monotherapy have passed week 12 shows that it is safe to continue the study an additional 30 patients will be included on top of the 104 patients needed for the primary endpoint analysis In contrast to the primary endpoint population these additional 30 patients will have a CD4 nadir 200 but a CD4 350 at the time of the screening visit Besides that these 30 patients will have to fulfill all other in and exclusion criteria of the primary endpoint population specifically a viral load never 100000 These 30 patients are part of a pilot study looking at the possibility to broaden the eligible population in a future larger randomized clinical trial
104 adults fulfilling the in and exclusion criteria and on stable cART will be randomized over 2 investigational arms
The first arm will contain the direct switch population This population will switch directly from stable cART to Dolutegravir mono-therapy on baseline visit
The second arm will contain the delayed-switch population This group will switch from stable cART to Dolutegravir monotherapy 24 weeks after baseline visit
The main goal is to investigate if Dolutegravir mono-therapy could be non-inferior to cART in virological suppressed HIV-1 infected adults
If a interim analysis performed when 40 patients on dolutegravir monotherapy have passed week 12 shows that it is safe to continue the study an additional 30 patients will be included on top of the 104 patients needed for the primary endpoint analysis In contrast to the primary endpoint population these additional 30 patients will have a CD4 nadir 200 but a CD4 350 at the time of the screening visit Besides that these 30 patients will have to fulfill all other in and exclusion criteria of the primary endpoint population specifically a viral load never 100000 These 30 patients are part of a pilot study looking at the possibility to broaden the eligible population in a future larger randomized clinical trial
Detailed Description:
DTG Monotherapy will be considered non-inferior to cART if the lower bound of the one sided 975CI for the difference in proportion of patients reaching the primary endpoint is not lower than -12 For this purpose a sample size of 52 per arm would provide 80 power at alpha 0025 to establish non-inferiority of DTG monotherapy compared with cART when the primary endpoint success rate is 95 in both treatment arms
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None